Pravastatin
- Generic Name
- Pravastatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H36O7
- CAS Number
- 81093-37-0
- Unique Ingredient Identifier
- KXO2KT9N0G
- Background
Pravastatin is the 6-alpha-hydroxy acid form of mevastatin. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers...
- Indication
Pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease. Its use includes the reduction of risk on myocardial infarction, undergoing myocardial revascularization procedures and cardiovascular mortality.
...
- Associated Conditions
- Acute Coronary Events, Cardiovascular Outcomes, Coronary Artery Atherosclerosis, Death, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Hyperlipidemias, Mixed Dyslipidemias, Myocardial Infarction, Myocardial Revascularization, Secondary prevention cardiovascular event, Stroke, Sudden Cardiac Death, Transient Ischemic Attack, Elevation of serum triglyceride levels
- Associated Therapies
- -
Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
- First Posted Date
- 2007-05-01
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- National Human Genome Research Institute (NHGRI)
- Target Recruit Count
- 3
- Registration Number
- NCT00467831
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia
- Conditions
- Interventions
- First Posted Date
- 2007-04-12
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 481
- Registration Number
- NCT00459745
- Locations
- 🇺🇸
East-West Medical Research Institute, Honolulu, Hawaii, United States
🇺🇸Welborn Clinic Gateway, Newburgh, Indiana, United States
🇺🇸Memorial Research Medical Clinic, Long Beach, California, United States
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Conditions
- Interventions
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 110
- Registration Number
- NCT00456365
- Locations
- 🇺🇸
University of Colorado at Denver and Health Sciences Center, Denver, Colorado, United States
Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- University College, London
- Target Recruit Count
- 846
- Registration Number
- NCT00433498
- Locations
- 🇬🇧
Walsall Manor Hospital, Walsall, England, United Kingdom
🇬🇧Weston General Hospital, Weston-super-Mare, England, United Kingdom
🇬🇧Addenbrooke's Hospital, Cambridge, England, United Kingdom
Anti-Oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study
- Conditions
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2006-10-06
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 100
- Registration Number
- NCT00384618
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, North Holland, Netherlands
Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22)
- Conditions
- First Posted Date
- 2006-09-29
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 4000
- Registration Number
- NCT00382460
This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.
- Conditions
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2006-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT00380939
- Locations
- 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States
Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 423
- Registration Number
- NCT00362206
- Locations
- 🇬🇷
Site 40, Athens, Greece
🇷🇴Site 5, Arad, Romania
🇷🇴Site 7, Bacau, Romania
Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease
- Conditions
- First Posted Date
- 2006-03-21
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- Pontificia Universidad Catolica de Chile
- Registration Number
- NCT00305201
- Locations
- 🇨🇱
Pontificia Universidad Catolica de Chile, School of Medicine, Santiago, Región Metropolitana, Chile
Do HMG CoA Reductase Inhibitors Affect Abeta Levels?
- First Posted Date
- 2006-03-16
- Last Posted Date
- 2010-04-13
- Target Recruit Count
- 35
- Registration Number
- NCT00303277
- Locations
- 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.